Form 4: Entrada Therapeutics Director Peter S. Kim Granted 19,000 Stock Options

Entrada Therapeutics, Inc. director Peter S. Kim was granted 19,000 stock options with an exercise price of $7.90, vesting on the earlier of June 11, 2026, or the next annual stockholders' meeting.

Summary

• Peter S. Kim, a Director of Entrada Therapeutics, Inc. (TRDA), was granted 19,000 stock options.
• The options have an exercise price of $7.90 per share.
• The grant date for these options was June 11, 2025.
• The options are exercisable on the earlier of the one-year anniversary of the grant date (June 11, 2026) or the Issuer's next annual meeting of stockholders.
• The options have an expiration date of June 11, 2035.
• Following this transaction, Peter S. Kim beneficially owns 19,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice for incentivizing management and aligning their interests with shareholders, indicating a routine compensation event rather than a significant positive or negative operational development.

Positives

• The grant of stock options to Director Peter S. Kim aligns his interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Negatives

• The issuance of new stock options could lead to minor future dilution for existing shareholders if exercised, although the impact from this single grant of 19,000 shares is likely minimal.

Risks

• The value of the stock options is dependent on the future stock price of Entrada Therapeutics, Inc., meaning they could become worthless if the stock price does not exceed the exercise price of $7.90.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Related Party Transactions

• The grant of stock options to a director is a related party transaction, as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Potential minor dilution upon exercise of options; increased alignment of director's interests with shareholder value.
• Employees: Not directly impacted by this specific director grant, but it reflects the company's compensation strategy for key personnel.

Next Steps

• The stock options will vest on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Peter S. Kim, Director, Stock Options, Insider Transaction, SEC Form 4, Equity Compensation, Corporate Governance, Beneficial Ownership